DIPRIVAN 1% 10 MG
PROPOFOL : 10 MG · DIN 02018950 · ASPEN PHARMACARE CANADA INC.
Health Canada status: MARKETED
What is DIPRIVAN 1%?
DIPRIVAN 1% 10 MG contains PROPOFOL : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02018950, held by ASPEN PHARMACARE CANADA INC., supplied as EMULSION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 16-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DIPRIVAN 1% used for?
DIPRIVAN 1% (propofol) is indicated for induction and maintenance of general anaesthesia, conscious sedation for surgical and diagnostic procedures, and sedation during intensive care. It can be used for both induction and maintenance of anaesthesia as part of a balanced anaesthesia technique, including total i.v. anaesthesia (TIVA), for inpatient and outpatient surgery. DIPRIVAN 1% may also be used for sedation during diagnostic procedures in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is DIPRIVAN 1% called?
The same molecule, PROPOFOL, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| PROPOFOL | Latin | Bahrain, Brazil |
| DIPRIVAN | Latin | Bahrain, Brazil, Morocco |
| ANESIA | Latin | Czechia, Saudi Arabia |
| LIPURO | Latin | Brazil |
| Propofol-Farmak | Latin | Saudi Arabia |
| Profast | Latin | Norway |
| PROPOFOL BAXTER | Latin | Czechia |
| Propofol-Lipuro | Latin | Bahrain, Norway |
| PROPOFOL MCT/LCT FRESENIUS | Latin | Czechia |
| PROPOVAN | Latin | Brazil |
| PROVIVE | Latin | Brazil |
| OPONAP® | Latin | Brazil |
| Propolipid | Latin | Norway |
| HYFOL | Latin | Brazil |
| POFOL | Latin | United Arab Emirates |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02018950 |
|---|---|
| Brand name | DIPRIVAN 1% |
| Generic / active ingredient | PROPOFOL : 10 MG |
| Manufacturer | ASPEN PHARMACARE CANADA INC. |
| Strength | 10 MG |
| Dosage form | EMULSION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | N01AX10 PROPOFOL |
| AHFS class | 28:04.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Jul-2018 |
| Original market date | 1993-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02018950 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2018950 |
| Brand name | DIPRIVAN 1% |
| Active ingredient / INN | PROPOFOL : 10 MG |
| ATC code | N01AX10 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N01 |
| AHFS class | 28:04.08 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | ASPEN PHARMACARE CANADA INC. |
How is it administered?
Individually titrated. Induction: ~40mg every 10s (adults <55). Maintenance: 0.1-0.2 mg/kg/min. ICU sedation: 0.005-0.050 mg/kg/min (max 4 mg/kg/h). Use aseptic technique.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
null
Which pack is which?
| Strength on the label | 10 MG |
|---|---|
| Dosage form | EMULSION |
| Route | INTRAVENOUS |
| Packaging as described in the monograph | null |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity to propofol, eggs, egg products, soybeans, or soy products. Contraindicated for sedation of children 18 years or younger receiving intensive care.
Warnings and precautions
Must be administered by persons trained in anaesthesia. Risk of fatal respiratory complications, hypotension, and sepsis if aseptic technique is not followed. Monitor for lipemia.
What can be used instead?
Other Canadian products sharing ATC code N01AX10 PROPOFOL. 4 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PROPOFOL INJECTION | 10 MG | EMULSION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02525879 |
| PROPOFOL INJECTION | 10 MG | EMULSION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02437643 |
| PROPOFOL INJECTION | 10 MG | EMULSION | BAXTER CORPORATION | MARKETED | DIN 02244379 |
| PROPOFOL | 10 MG | EMULSION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 02468336 |
| PROPOFOL INJECTION | 10 MG | EMULSION | STERIMAX INC | APPROVED | DIN 02559692 |
| PROPOFOL INJECTION | 10 MG | EMULSION | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 02241504 |
| PROPOFOL INJECTION | 10 MG | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 02242973 |
| PROPOFOL INJECTION | 10 MG | EMULSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02236887 |
| PROPOFOL-II INJECTION | 10 MG | EMULSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02376865 |
| TEVA-PROPOFOL | 10 MG | EMULSION | TEVA CANADA LIMITED | DORMANT | DIN 02437961 |
Who else supplies PROPOFOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PROPOFOL appears in 1483 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does PROPOFOL cost around the world?
PROPOFOL is listed on 13 national price registers Nexara tracks, across 189 pack listings published on 12 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Brazil | preco fabrica (ex-factory ceiling) | 10 | 43 | 02 Sep 2026 |
| Saudi Arabia | public | 14 | 28 | 01 Sep 2026 |
| South Africa | single exit price | 18 | 27 | 01 Sep 2026 |
| Czechia | max producer price (ex-factory) | 3 | 17 | 03 Sep 2026 |
| Italy | ex-factory (classe H) | 17 | 17 | 02 Sep 2026 |
| Greece | producer price (ex-factory) | 14 | 14 | 03 Sep 2026 |
| Norway | max AUP (pharmacy retail) | 3 | 13 | 07 Sep 2026 |
| Bahrain | retail (max) | 6 | 9 | 01 Sep 2026 |
| United Arab Emirates | public | 5 | 7 | 31 Aug 2026 |
| Romania | max producer price | 3 | 6 | 03 Sep 2026 |
| United States | acquisition | 2 | 5 | 03 Sep 2026 |
| Morocco | PPV (public price) | 1 | 2 | 05 Sep 2026 |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.